AR100128A1 - GEL ELABORATION METHOD WITH GONADOTROPINE LIBERATING HORMONE (GNRH) - Google Patents
GEL ELABORATION METHOD WITH GONADOTROPINE LIBERATING HORMONE (GNRH)Info
- Publication number
- AR100128A1 AR100128A1 ARP150101166A ARP150101166A AR100128A1 AR 100128 A1 AR100128 A1 AR 100128A1 AR P150101166 A ARP150101166 A AR P150101166A AR P150101166 A ARP150101166 A AR P150101166A AR 100128 A1 AR100128 A1 AR 100128A1
- Authority
- AR
- Argentina
- Prior art keywords
- volume
- weight
- certain amount
- gel
- mixture
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un proceso para la elaboración de un gel con una hormona liberadora de gonadotropina a partir de un lote de mezcla de composición primaria de un producto farmacéutico que comprende la etapa de mezclado adicional del lote de mezcla de la composición primaria. Reivindicación 4: El proceso conforme la reivindicación 1 en donde la hormona liberadora de gonadotropina es triptorelina. Reivindicación 11: El proceso de la reivindicación 10 en donde el agente gelificante es una celulosa y la celulosa es metilcelulosa. Reivindicación 16: El proceso de la reivindicación 15 en donde la mezcla comprende triptorelina en cierta cantidad de aproximadamente 0,01% en peso por volumen (como el acetato), metilparabeno en cierta cantidad de aproximadamente 0,09% en peso por volumen, propilparabeno en cierta cantidad de aproximadamente 0,01% en peso de volumen, cloruro de sodio en cierta cantidad de aproximadamente 0,91% en peso por volumen, L-metionina en cierta cantidad de aproximadamente 0,1% en peso por volumen, citrato de sodio en cierta cantidad de aproximadamente 0,186% en peso por volumen, ácido cítrico en cierta cantidad de aproximadamente 0,07% en peso por volumen, y metilcelulosa en cierta cantidad de aproximadamente 1,2% en peso por volumen. Reivindicación 21: El proceso de cualquiera de las reivindicaciones 1 - 20, que comprende mezclar la mezcla utilizando un CMM por un período de aproximadamente 90 a aproximadamente 100 minutos.Claim 1: A process for making a gel with a gonadotropin releasing hormone from a batch of primary composition mixture of a pharmaceutical product comprising the additional mixing step of the mixture batch of the primary composition. Claim 4: The process according to claim 1 wherein the gonadotropin releasing hormone is triptorelin. Claim 11: The process of claim 10 wherein the gelling agent is a cellulose and the cellulose is methylcellulose. Claim 16: The process of claim 15 wherein the mixture comprises triptorelin in a certain amount of about 0.01% by weight by volume (such as acetate), methylparaben in a certain amount of about 0.09% by weight by volume, propylparaben in a certain amount of about 0.01% by weight of volume, sodium chloride in a certain amount of about 0.91% by weight by volume, L-methionine in a certain amount of about 0.1% by weight by volume, citrate of sodium in a certain amount of about 0.186% by weight by volume, citric acid in a certain amount of about 0.07% by weight by volume, and methylcellulose in a certain amount of about 1.2% by weight by volume. Claim 21: The process of any one of claims 1-20, comprising mixing the mixture using a CMM for a period of about 90 to about 100 minutes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981370P | 2014-04-18 | 2014-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100128A1 true AR100128A1 (en) | 2016-09-14 |
Family
ID=58700148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101166A AR100128A1 (en) | 2014-04-18 | 2015-04-17 | GEL ELABORATION METHOD WITH GONADOTROPINE LIBERATING HORMONE (GNRH) |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR100128A1 (en) |
-
2015
- 2015-04-17 AR ARP150101166A patent/AR100128A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| CL2018001474A1 (en) | Dry mixture comprising alginate salt; galactamannan hydrocolloid vegetable gum; and starch for the manufacture of an alginate composition for wrapping food products which also comprises: polyol; liquid smoke; and a buffering agent such as glucono-delta-lactone, acetic acid, and sodium carbonate (divisional from 408-2017). | |
| CR20170361A (en) | DOSAGE FORM INCLUDING A SOLID SOLUTION OF AMORPH DRUGS | |
| UY35907A (en) | NEW INDAZOLCARBOXAMIDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
| CO2020001927A2 (en) | Production method of pharmaceutical compositions comprising the immunogenic chikungunya virus chikv-delta5nsp3 | |
| AR098576A1 (en) | PHARMACEUTICAL PRODUCT | |
| EA201692334A1 (en) | CORTICOSTEROID COMPOSITIONS FOR LOCAL APPLICATION | |
| EA201791555A3 (en) | METHOD OF MAKING PRODUCT CONTAINING GLATIRAMER ACETATE | |
| EA201791537A1 (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION | |
| BR112016022394A2 (en) | PHARMACEUTICALLY ACCEPTABLE COMPOSITION, COMPOSITION IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE INJECTABLE SOLUTION, USE OF THE COMPOSITION, AND METHOD FOR PREPARING THE PHARMACEUTICALLY ACCEPTABLE INJECTABLE COMPOSITION | |
| EA202090508A1 (en) | PRODUCTION OF PHARMACEUTICAL COMPOSITIONS | |
| RU2019110980A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION | |
| BR112021019903A2 (en) | Aqueous pharmaceutical composition, use of the aqueous pharmaceutical composition and method of producing an aqueous pharmaceutical composition | |
| CL2016001375A1 (en) | Composition, which comprises bioactive agent (immunogen) dispersed in oil droplets, enteric coating polymer, a mucoadhesive polymer, its method of preparation and use for oral administration of a bioactive agent. | |
| CY1124893T1 (en) | MAROPITANTIS MEDICINAL MIXTURE | |
| MX2015010486A (en) | Chewable composition for oral administration and process for preparing thereof. | |
| AR100128A1 (en) | GEL ELABORATION METHOD WITH GONADOTROPINE LIBERATING HORMONE (GNRH) | |
| MX2020006075A (en) | Bendamustine pharmaceutical compositions. | |
| CL2022003426A1 (en) | Levilimab Aqueous Pharmaceutical Composition and Its Use | |
| BR112018008769A2 (en) | pharmaceutical formulations, reconstituted and lyophilized aqueous liquid formulations, syringe, method of manufacturing a pharmaceutical formulation, method for treating a disease and use of a reconstructed formulation | |
| MX2017004242A (en) | Dissolution testing of hydrophobic active pharmaceutical ingredients such as avermectins with or without pyrantel. | |
| MX2017007567A (en) | A pharmaceutical composition for treating gastrointestinal diseases. | |
| MX2022013576A (en) | Composition for controlled release of physiologically active substances and process for its preparation. | |
| CO2017003313A2 (en) | A process for the production of complexes of n-acetyl-aspartylated iron (iii) casein and its use in pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |